Get startedLog in
    Picture of Swedish Orphan Biovitrum AB (publ) logo

    SOBI — Swedish Orphan Biovitrum AB (publ) News Story

    0.000.00%
    se flag iconLast trade - 00:00
    HealthcareBalancedLarge CapHigh Flyer
    All News

    Brief: SOBI Announces FDA Acceptance Of New Drug Application For Avatrombopag

    Picture of Swedish Orphan Biovitrum AB (publ) logoSwedish Orphan Biovitrum AB (publ)
    12/12/2024 13:01
    Dec 12 (Reuters) - Swedish Orphan Biovitrum AB (publ)
 SOBIV.ST :
    * SOBI ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION FOR
AVATROMBOPAG (DOPTELET®) FOR THE TREATMENT OF PEDIATRIC IMMUNE
THROMBOCYTOPENIA
    * SWEDISH ORPHAN BIOVITRUM AB (PUBL) - FDA SETS PDUFA TARGET
ACTION DATE FOR JULY 24, 2025

Source text:  ID:nGNX3GPkT4 
Further company coverage:  SOBIV.ST 

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Swedish Orphan Biovitrum AB (publ)

    See all news